Insperity, Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Insperity, Inc. (NSP).

If you purchased or held Insperity, Inc. securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Insperity, Inc.

Insperity, Inc. is a professional employer organization (PEO) that provides a range of human resources and business performance solutions. The company’s services are designed to help businesses manage employment costs, including health insurance, payroll, and other HR functions.

Insperity, Inc. is publicly traded under the ticker symbol NSP.

Items Under Investigation

Lawyers are currently investigating potential issues related to Insperity’s public statements and disclosures regarding its financial performance and outlook during 2025. The investigation may focus on whether the company made misleading statements or omitted key information about rising healthcare costs and their impact on profitability.

On April 29, 2025, Insperity announced its first quarter 2025 results, reporting an EPS of $1.57, which fell short of the $2.02 expected by analysts. The company also modestly revised its 2025 outlook and noted higher healthcare costs. Following this announcement, the stock price dropped approximately 12.6 percent, closing at around $68.70.

The investigation could also examine when Insperity released its second quarter results. The company reported adjusted EPS of $0.26, missing expectations of $0.41 by about 36.6 percent. This announcement triggered a sharp sell-off, with the share price falling about 14.6 percent in pre-market trading and ultimately closing at $45.07, representing a $14.51 or 24.35 percent drop from the prior close. With approximately 37.2 million shares outstanding, this decline implied a loss of roughly $540 million in market value.

Legal professionals might examine whether Insperity made material misstatements or omitted important information regarding its cost structure. For example, in the April 29, 2025 earnings release and call, the company projected full-year 2025 EPS of $2.23–$3.28, suggesting only modest expense pressures. CFO James Allison reiterated these projections and forecasted only 6.5–7.5 percent growth in benefits cost per employee. However, by the second quarter, the company disclosed that benefits costs had exceeded forecasts by $12 million and were already beyond prior ranges. The Q2 2025 results admitted that gross profit fell 14 percent “due primarily to higher-than-expected benefits costs” driven by “elevated pharmacy trends and [big] claim activity”. Management also slashed full-year 2025 adjusted EPS guidance to only $1.81–$2.51.

Attorneys could also investigate whether statements by CEO Paul Sarvadi and CFO Allison about growth momentum and retention were inconsistent with the undisclosed cost escalation. For instance, on the April 29 call, Allison stated “no significant plan design changes were initiated this year,” suggesting cost management until 2026, a statement that appears inconsistent with the rapid cost escalation later revealed.

Your Rights and Next Steps

Investors who purchased or held Insperity, Inc. securities between April 29, 2025 and August 1, 2025 and suffered financial losses may have important legal rights. This is an active investigation, not a filed lawsuit, but it could result in a class action seeking compensation for affected shareholders.

Lawyers are ready to help investors understand their options. Those who join the investigation may be able to participate in any future class action and seek recovery for their losses. It is important for investors to act promptly, as securities investigations are often time-sensitive and may have strict deadlines for participation.

If you have questions about your rights or eligibility, legal professionals can review your transactions and advise on next steps. Investors are encouraged to gather their records of Insperity, Inc. stock purchases and sales during the class period and consider submitting a claim.

You May Be Entitled to Compensation

If you purchased or held Insperity, Inc. securities between April 29, 2025 and August 1, 2025 and suffered losses, you may be eligible to join this investigation and seek compensation. Securities investigations can move quickly, and your ability to participate may depend on timely action.

To join the investigation or to learn more, complete the form below.